(Reuters) – Smith+Nephew warned on Thursday the impact of the COVID-19 pandemic is likely to continue into the first half of 2021 and that it was uncertain on the timing of recovery, as the medical products maker posted a drop in annual trading profit.
The British company, however, said it expects substantial underlying revenue growth in 2021, with its hip implants business outperforming knee implants, its sports medicine & ENT franchise performing strongly on market recovery and also forecasts better growth in its advanced wound-management business.
“We start 2021 with three clear priorities: to return to top-line growth and recapture momentum; to drive further operational improvement; and to continue to respond effectively to COVID-19,” Chief Executive Officer Roland Diggelmann said, adding that the company also expects 2021 profit margins to improve.
The company, a maker of orthopaedic implants and prosthetics, along with wound dressings and other surgical technologies, said trading profit slumped 42% to $683 million for the year ended Dec. 31, missing analyst estimates of $712 million.
Smith+Nephew said its fourth-quarter performance was hit by rising COVID-19 cases from mid-October, particularly in the United States and Europe, as hospitals and patients delayed elective surgeries.
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.